Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine plus bupivacaine versus bupivacaine alone for paravertebral block in thoracoscopic surgery
ChiCTR2500096090Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2025
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liposomal bupivacaine and bupivacaine in postoperative pain (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Postoperative 48-hour movement pain AUC. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
liposomal bupivacainebupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2500096090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096090.